The 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP)-induced parkinsonism model, particularly in non-human primates, remains the gold-standard for studying the pathogenesis and assessing novel therapies for Parkinson's disease. However, whether the loss of dopaminergic neurons in this model is progressive remains controversial, mostly due to the lack of objective in vivo assessment of changes in the integrity of these neurons. In the present study, parkinsonism was induced in cynomolgus monkeys by intravenous administration of MPTP (0.2 mg/kg) for 15 days; stable parkinsonism developed over 90 days, when the symptoms were stable. 
INTRODUCTION
Parkinson's disease (PD) is one of the most common neurodegenerative disorders and affects ~2% of the world's population aged over 65 [1] . The cardinal clinical symptoms are bradykinesia, tremor, rigidity, and postural instability with the pathological characteristic of evolutional nigrostriatal dopaminergic neurodegeneration [2, 3] . 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces parkinsonism in both humans [4] and non-human primates [5] with the cognitive, biochemical, histological and classical behavioral changes that occur in PD [6] . Increasing evidence has suggested that single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging can be used to sensitively and objectively evaluate the integrity of the nigrostriatal dopaminergic system and may be useful tools for providing diagnostic information on PD [7] [8] [9] [10] . There are numerous SPECT and PET imaging tracers for monitoring the integrity of dopaminergic neurons. 6-[ 18 F]fluoro-DOPA has been used to evaluate dopamine synthesis [11] , 123 I-
targets the membrane dopamine transporter [12, 13] , [ 11 C]-raclopride [14] specifi cally binds to dopamine receptors, and 
MATERIALS AND METHODS

Animals
Nine 10-15-year-old cynomolgus monkeys (5.2-8.0 kg, 2 females and 7 males) were purchased from Grandforest
Co. (Nanning, China), a local primate-breeding company.
All the animals were healthy, without any physical injury.
For MPTP administration, the animals were anesthetized with a mixture of 3% isoflurane and 97% O 2 prior to treatment, and a low level of isofl urane (1%) was continued for maintenance. MPTP was injected intravenously as MPTP-HCl (Sigma Aldrich, St. Louis, MO) diluted in sterile saline at 0.2 mg/kg. Injection was performed daily for 15 days. No animal was euthanized in this study.
Ethics Statement
All animals were housed with a 12:12 h light/dark cycle at the facility of Wincon TheraCells Biotechnologies Co., Ltd., 
Radiosynthesis of [ 18 F]AV-133
Radiosynthesis of [ 18 F]AV-133 was carried out on a custommade automated radiosynthesis apparatus according to a previously described method [24] . The mesylate precursor of The mean specifi c radioactivity was 1000 Ci/mmol.
PET Image Acquisition and Analysis
Each monkey underwent three injection according to our preliminary study [25] .
The data were reconstructed using a 3D iterative algorithm after correction for randomness, scatter, and attenuation. All PET scans were analyzed simultaneously following the same protocol. Because of the negligible density of VMAT2 in the cerebellum, this region was used as a nonspecifi c reference. Two irregular regions of interest encompassing the whole right and left striatum were drawn on four consecutive slices through the striatum, and the background was readily identifi ed and delineated on the cerebellum guided by detailed CT images and with reference to a stereotaxic brain atlas [26, 27] . The results are expressed as SUr, calculated as: (mean striatal uptake − mean cerebellar uptake)/mean cerebellar uptake [22] , and dopaminergic denervation severity (DS) after MPTP treatment, calculated from SUr: (SUr baseline − SUr lesioned )/ SUr baseline [28, 29] .
Clinical Rating Scores
The behavioral changes were observed and quantified twice a week on a previously-validated parkinsonian monkey clinical rating scale [30, 31] . Animal behaviors in corresponds to severe disability. The scores were rated by both an experienced neurologist and a technician who were blinded to the study protocol.
Statistical Analysis
Comparisons of group characteristics were performed with paired-sample t-tests. Correlations between the clinical data and PET imaging results were evaluated using nonparametric Pearson analysis. P <0.05 was defi ned as statistically signifi cant. Data are presented as mean ± SD.
RESULTS
PET Images
The images from PET scans at different time points ( (Fig. 3) . At 90 days, when the parkinsonian symptoms were stable, a further reduction in striatal uptake was found. The right and left striatal SUrs were 0.26 ± 0.13 (t = 8.179, P = 0.000) and 0.24 ± 0.16 (t = 7.828, P = 0.000) (n = 9) (Fig. 2) , and the right and left DSs were 0.84 ± 0.11 (t = 20.534, P = 0.000) and 0.84 ± 0.12 (t = 20.773, P = 0.000) (n = 9), respectively ( Fig.   3) . The values of [ 18 F]AV-133 uptake in the striatum did not overlap between baseline and 90 days (Fig. 2) .
Correlation between [ 18 F]AV-133 Uptake and Clinical
Rating Scores
At 15 days, the mean total clinical rating score was 14.56 ± 6.76. The increased DSs in the right side striatum were accompanied by signifi cantly increased total clinical rating scores and bradykinesia subscores. Also, significant correlations were found between SUrs of right side striatum and clinical rating scores and bradykinesia subscores.
However, no significant correlation was found between the rigidity subscores and SUrs or DSs of the right side striatum (Fig. 4) .
At 90 days, when stable experimental parkinsonism was developed, the mean total clinical rating score reached 22.19 ± 5.34. The clinical rating scores and subscores for rigidity and bradykinesia were all positively correlated with DSs (right side), and signifi cant negative trends were found for SUrs (right side) (Fig. 5) .
DISCUSSION
The MPTP-lesioned monkeys showed degeneration of nigrostriatal dopaminergic neurons, as seen in PD patients.
The present data confi rmed that AV-133 uptake assessed here is consistent with previous studies of the primate brain [21, 25, 32] . MPTP administration induced striatal dopaminergic denervation, and resulted in a decrease in VMAT2 expression (Fig. 2) . After 15 days of MPTP exposure, the SUrs of right and left side striatum of PD patients, next in the anterior putamen (−70%), and then in the caudate nucleus (−48%) [23] , which is consistent with our results. In 2010, [ 11 C]DTBZ PET imaging was used to evaluate the model of chronic MPTP-induced parkinsonism in monkeys induced by a low dose of MPTP administered over several months [33] . Different from the previous study, we used a model of acute infusion of MPTP (0.2 mg/kg/day for 15 days), which is the standard model for anti-parkinsonian drug studies. In the Obeso study, the comparisons were made among four groups, controls, asymptomatic, recovered, and stable parkinsonism [34] .
In the present study, changes of monkeys appeared to have parkinsonian symptoms, and reached a score >8 on their clinical rating scale [6] . . This is consistent with previous studies on PD patients [23] . On day 15, no significant correlation was found between the subscores for rigidity 
